Measurable Residual Disease Adapted Consolidation Strategy After Quadruplet Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma By Ogkologos - July 8, 2025 512 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MIDAS study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Pembrolizumab Now Second Immunotherapy Approved to Treat Merkel Cell Carcinoma February 4, 2019 Low Dose Dexamethasone Effective as Premedication for Taxanes to Prevent Hypersensitivity... August 10, 2021 Teenage (…and young adult) kicks April 5, 2023 How to Provide Support as a Long-Distance Cancer Caregiver January 25, 2021 Load more HOT NEWS Improving research with registered reports Gilteritinib Improves Survival in AML with FLT3 Mutations New Safety Signal for Use of Ibrutinib in Combination with Rituximab... Breast cancer surgery: ‘I’m proud of the tattoos inked across my...
